Printer Friendly

IMPROVED AIR PRESSURE SYSTEM REDUCES RISK OF HYPOXEMIA DURING LUNG SURGERY

 IMPROVED AIR PRESSURE SYSTEM REDUCES RISK
 OF HYPOXEMIA DURING LUNG SURGERY
 ST. LOUIS, March 27 /PRNewswire/ -- A new airway system that improves oxygenation of the blood is being introduced by Mallinckrodt Medical, Inc. for use in surgical procedures that require one-lung anesthesia. The new disposable continuous positive airway pressure (CPAP) System is designed for use with the Broncho-Cath (R) double-lumen endotracheal tubes to help prevent hypoxemia -- oxygen deficiency in the bloodstream -- during pulmonary surgery.
 During surgery that requires one-lung ventilation, only one lung is available to supply oxygen to the blood and oxygen levels in the bloodstream are, therefore, reduced. Hypoxemia occurs when oxygen levels in the bloodstream fall below what is considered safe (60 to 70 mm Hg). Although a crisis occurs in less than 10 percent of patients, hypoxemia can result in brain damage and even death.
 Traditionally, physicians have used personally assembled systems from component parts to deliver continuous positive airway pressure (CPAP) to treat hypoxemia when it occurred. These systems, however, are cumbersome, expensive, often not available when needed, and are not always effective enough to allow the operation to continue without interruption. The introduction of Mallinckrodt Medical's CPAP System allows for the continuous supply of oxygen at low pressure to the non- ventilated lung, thereby reducing the risk of hypoxemia during surgery. The CPAP holds open, non-ventilated air sacs within the operated lung and allows oxygen to enter the bloodstream.
 The adjustable valve on Mallinckrodt Medical's CPAP System supplies an easily identifiable range of pressures from 10 centimeter (cm) to one cm of water pressure, lower than any other CPAP device. This represents an important advantage because oxygenation at this range of low pressures will help meet the specific surgical and physiological needs of each procedure. "By supplying a continuous flow of oxygen under low pressure, the anesthesiologist can prevent hypoxemia instead of having to interfere with the surgery to treat oxygen deficiency once it has occurred," according to David Alfery, M.D., who developed the concept of the CPAP system.
 Dr. Alfery has entered into a licensing agreement with Mallinckrodt Medical to manufacture and market the patented device. The CPAP System is currently available in the United States and will likely be available internationally this summer. Since many anesthesiologists do not yet use CPAP technology on a routine basis, the Anesthesiology Division of Mallinckrodt Medical is providing an instructional video to anesthesiologists on the routine operation of the device.
 "Because non-dependent lung CPAP has been shown to relieve hypoxemia consistently and reliably during one-lung ventilation, its routine use to prevent hypoxemia during thoracic surgery using double-lumen endotracheal tubes should be considered," according to Jonathan L. Benumof, M.D., a noted expert on one-lung anesthesia at the University of California, San Diego.
 Mallinckrodt Medical sells 90 percent of the double-lumen endotracheal tubes used in the United States. "The goal is to provide a disposable CPAP System for use with our Broncho-Cath endobronchial tube," explains Dan Flynn, marketing manager of Mallinckrodt Medical's Anesthesiology division. "We expect this system will help increase patient safety and well-being by dramatically reducing the risk of hypoxemia during surgery requiring one-lung ventilation."
 Mallinckrodt Medical is a St. Louis business unit of IMCERA Group Inc. of Northbrook, Ill. The company is a leading, worldwide producer of products used in anesthesiology, radiology, cardiology, nuclear medicine and critical care procedures.
 -0- 3/27/92
 /CONTACT: Roxanna Motchan of Mallinckrodt Medical, 314-895-2078/
 (IMA) CO: Mallinckrodt Medical, Inc. ST: Missouri IN: MTC SU: PDT


PS-TQ -- NY003 -- 2230 03/27/92 08:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 27, 1992
Words:587
Previous Article:REPUBLICAN LEADERS DISCUSS PROBLEMS WITH THE FAIR ACT
Next Article:HERBALIFE REPORTS SIGNIFICANT INCREASE FOR 1991 SALES AND EARNINGS
Topics:


Related Articles
AORTECH ENTERS CIRCULATORY SUPPORT MARKET
CLINICAL STUDIES DEMONSTRATE THAT SURGICAL PATIENT WARMING IMPROVES MEDICAL OUTCOMES AND COST SAVINGS
MicroPulse Unveils First Patient Support System Clinically Shown to Prevent Pressure Ulcers
Medtronic Announces Commercial Release Of New Cardioplegia System That Helps Make Surgery Safer
Focal, Inc. Completes Enrollment in Pivotal U.S. Clinical Trial of FocalSeal-L Surgical Sealant
FDA Grants Focal, Inc. 'Expedited Review' of PMA Application For FocalSeal-L(R) Surgical Sealant.
Focal, Inc. Surgical Sealant European Clinical Results Published in the Official Journal of The American Association of Thoracic Surgery.
Focal, Inc. Surgical Sealant Launched in New International Markets.
Focal, Inc. Completes PMA Submission for FocalSeal(R)-L Surgical Sealant.
FDA Panel Recommends Approval with Certain Conditions Of FocalSeal(R)-L Synthetic Surgical Sealant.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters